OzempicvsWegovy

Ozempic's active ingredient, semaglutide, is a GLP-1 receptor agonist: it mimics glucagon-like peptide-1, a natural gut hormone released after eating. It prompts the pancreas to release more insulin when blood sugar is high, suppresses glucagon (a hormone that raises blood sugar), and slows stomach emptying. It also acts on appetite centers in the brain to reduce hunger and food intake, which is why many people eat less and lose some weight.

Wegovy's active ingredient, semaglutide, mimics a natural gut hormone called GLP-1 (glucagon-like peptide-1). By activating GLP-1 receptors in the brain's appetite centers, it reduces hunger, increases feelings of fullness, and slows how quickly the stomach empties. The result is that most people naturally eat less and feel satisfied on smaller portions. It also improves how the body handles blood sugar. Because it does not "burn fat" directly, it works largely by lowering calorie intake, which is why diet and physical activity remain part of treatment.

Across the SUSTAIN clinical trial program, Ozempic lowered A1C by roughly 1.0 to 1.8 percentage points depending on dose and starting level, with average weight reductions of about 6 to 14 lb (roughly 2.5 to 6.5 kg) at the 0.5 mg and 1 mg doses, and more at 2 mg. In the SUSTAIN-6 cardiovascular outcomes trial (3,297 patients with type 2 diabetes at high cardiovascular risk, published in NEJM in 2016), semaglutide reduced the primary composite of cardiovascular death, nonfatal heart attack, or nonfatal stroke by 26% versus placebo (6.6% vs 8.9%; hazard ratio 0.74, 95% CI 0.58 to 0.95). That composite benefit was driven mainly by a significant drop in nonfatal stroke; reductions in nonfatal heart attack and cardiovascular death individually were not statistically significant, and the trial notably found a higher rate of diabetic retinopathy complications in the semaglutide group. SUSTAIN-6 was designed as a safety (non-inferiority) trial that went on to show superiority on the composite. The separate 2024 FLOW trial showed a 24% reduction in a combined kidney-and-cardiovascular outcome, supporting the 2025 chronic kidney disease indication.

In the pivotal STEP 1 trial (NEJM, 2021; 1,961 adults with overweight or obesity but without diabetes), weekly semaglutide 2.4 mg produced an average weight loss of about 14.9% of body weight at 68 weeks versus roughly 2.4% with placebo, and about 86% of treated participants lost at least 5% of their body weight. The 2-year STEP 5 trial (Nature Medicine, 2022) showed sustained results with continued use: about 15.2% mean weight loss versus 2.6% with placebo at 104 weeks. In the large SELECT cardiovascular outcomes trial (NEJM, 2023; 17,604 adults with established cardiovascular disease, overweight or obese, without diabetes), semaglutide reduced major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) by 20% versus placebo (hazard ratio 0.80). The newer oral Wegovy 25 mg pill produced about 16.6% mean weight loss among participants who adhered to treatment in the OASIS 4 trial. Individual results vary.

The most common side effects (reported in at least 5% of patients) are gastrointestinal: nausea (about 16-20%), vomiting, diarrhea, abdominal pain, and constipation. These are usually worst early on or after a dose increase and often ease over time; eating smaller, lower-fat meals can help. Serious but less common risks include pancreatitis (severe, persistent abdominal pain), gallbladder problems, acute kidney injury from dehydration, low blood sugar (especially when combined with insulin or sulfonylureas), worsening diabetic retinopathy, and allergic reactions. Ozempic carries an FDA boxed warning because semaglutide caused thyroid C-cell tumors in rodents; whether it does so in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Tell your doctor about any persistent abdominal pain, vision changes, or signs of an allergic reaction.

The most common side effects (each occurring in 5% or more of users in trials) are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, bloating, and indigestion, along with headache, fatigue, and dizziness. These are usually mild to moderate, tend to be worst when starting or increasing the dose, and often ease over a few weeks. Serious but less common risks include pancreatitis, gallbladder problems (including gallstones), acute kidney injury from dehydration caused by vomiting or diarrhea, low blood sugar (mainly in people also taking diabetes medications such as insulin or sulfonylureas), and worsening of diabetic eye disease. Wegovy carries a boxed warning for thyroid C-cell tumors based on rodent studies; whether this risk applies to humans is not known. Seek medical care promptly for severe, persistent abdominal pain (a possible sign of pancreatitis). This is not a complete list; review the full label and discuss risks with your prescriber.

As of September 2026, NovoCare Pharmacy sells Ozempic to self-pay patients for $349/month (0.25, 0.5 or 1 mg pens) and $499/month (2 mg), and new patients pay $199/month for their first two fills of 0.25 mg or 0.5 mg through December 31, 2026. The Ozempic pill costs $149–$299/month depending on dose. The list price is roughly $1,000 per pen package — close to what an uninsured patient pays at a regular pharmacy counter without these programs. Commercially insured patients may pay less with the manufacturer savings card (caps apply; not available with government insurance). Medicare and Medicaid typically cover Ozempic for type 2 diabetes but not for weight loss. Confirm pricing and coverage before starting.

As of September 2026, Wegovy's list price is $1,349.02 per package, but cash-paying patients rarely pay that: NovoCare's self-pay price is $349/month for the 0.25–2.4 mg pens and $399/month for Wegovy HD 7.2 mg, and new patients pay $199/month for their first two fills of 0.25 mg or 0.5 mg through December 31, 2026. The Wegovy pill has separate self-pay pricing starting at $149/month. With commercial insurance that covers Wegovy, the manufacturer savings card can lower the copay further for eligible patients, but many plans — and most Medicare and Medicaid plans — still exclude weight-loss drugs. Verify pricing for your dose with NovoCare before starting.

Ozempic is FDA-approved for adults with type 2 diabetes to improve blood sugar control, to reduce major adverse cardiovascular events in those who also have established cardiovascular disease, and (since January 2025, based on the FLOW trial) to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in those with type 2 diabetes and chronic kidney disease. It is not approved for type 1 diabetes or for weight loss on its own. Do NOT use it if you or a family member has had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to semaglutide. Use caution with a history of pancreatitis, diabetic retinopathy, or gallbladder disease, and discuss pregnancy plans with your doctor. Your prescriber makes the final eligibility call.

Wegovy is FDA-approved for adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) who also have a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol, used alongside a reduced-calorie diet and increased physical activity. It is also approved to reduce the risk of major cardiovascular events in adults with established cardiovascular disease who are overweight or obese, and for adolescents aged 12 and older with obesity. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in those with a known serious allergy to semaglutide or any Wegovy ingredient. It should not be used during pregnancy; because of semaglutide's long half-life, the label advises stopping at least 2 months before a planned pregnancy. Use cautiously, and under close supervision, with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, kidney problems, or diabetic retinopathy. A clinician determines eligibility.